XML 55 R35.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Commitments and Contingencies (Details Textual) - USD ($) |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 06, 2017 | Jan. 09, 2017 | Aug. 04, 2016 | Feb. 27, 2014 | Sep. 30, 2016 | Aug. 31, 2016 | Jul. 24, 2012 | Jun. 15, 2012 | Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2016 | Feb. 16, 2016
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee payment |  |  |  |  |  |  |  |  |  |  | $ 7,529 |  |  |
Research recorded fees |  |  |  |  |  |  |  |  | $ 4,379,047 | $ 4,147,945 | 8,883,398 | $ 7,913,397 |  |
Cost of lease agreement | $ 312,660 |  |  |  |  | $ 2,400 |  |  |  |  |  |  |  |
Accounts payable and accrued expenses |  |  |  |  |  |  |  |  | 3,604,579 |  | 3,604,579 |  | $ 4,194,874 |
Lease term | 7 years 3 months |  |  |  |  |  |  |  |  |  |  |  |  |
Lease agreements, Description | The first 4 years, and an annual rate of $341,610 for the remaining period. |  |  |  |  |  |  |  |  |  |  |  |  |
Lines of credit |  |  |  |  |  |  |  |  |  |  | 390,825 |  |  |
Deposit |  |  |  |  |  |  |  |  | 390,825 |  | 390,825 |  |  |
Manufacturing Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Project estimated cost |  |  |  | $ 6,800,000 |  |  |  |  |  |  | 2,500,000 |  |  |
Non - refundable institutional fee |  |  |  | $ 600,000 |  |  |  |  |  |  |  |  |  |
Total project estimated to cost |  |  |  |  |  |  |  |  | 100,000 |  | 100,000 |  | $ 100,000 |
Research and development costs |  |  |  |  |  |  |  |  |  |  | 300,000 | 200,000 |  |
CRO Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Project estimated cost |  |  | $ 4,600,000 |  |  |  |  |  |  |  | 200,000 |  |  |
AbbVie Biotherapeutics Corp [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones Payments |  |  |  |  |  |  |  |  |  |  | 7,750,000 |  |  |
AbbVie Biotherapeutics Corp [Member] | Product Development and Patent License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee payment |  |  |  |  |  |  |  |  |  |  | 3,000,000 |  |  |
Milestones Payments |  |  |  |  |  |  |  |  |  |  | $ 7,750,000 |  |  |
Description of royalty payment |  |  |  |  |  |  |  |  |  |  | The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. |  |  |
Royalty of net sales percentage |  |  |  |  |  |  |  |  |  |  | 12.00% |  |  |
First commercial sale period |  |  |  |  |  |  |  |  |  |  | 12 years 6 months |  |  |
AbbVie Biotherapeutics Corp [Member] | After first net sales [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones Payments |  |  |  |  |  |  |  |  |  |  | $ 1,500,000 |  |  |
AbbVie Biotherapeutics Corp [Member] | Phase 1 Clinical Trial of a licensed product [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones Payments |  |  |  |  |  |  | $ 750,000 |  |  |  | 750,000 |  |  |
Accounts payable and accrued expenses |  |  |  |  |  |  |  |  | 750,000 |  | 750,000 |  |  |
AbbVie Biotherapeutics Corp [Member] | Phase 2 Clinical Trial of a licensed product [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones Payments |  |  |  |  |  |  |  |  |  |  | 750,000 |  |  |
Research and development costs |  |  |  |  | $ 750,000 |  |  |  |  |  |  |  |  |
Abbott Biotherapeutics Corp [Member] | After first net sales [Member] | Product Development and Patent License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales in milestones payment |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |
Oak Ridge National Laboratory [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  | $ 700,000 |  |  |  |  |  |  |  |  | $ 300,000 | 300,000 |  |
Icon Clinical Research [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Down payment of project estimated cost percentage |  |  |  |  |  |  |  |  |  |  | 12.50% |  |  |
Down payment for project |  |  |  |  |  |  |  |  |  |  | $ 1,900,000 |  |  |
Down payment paid in 2007 and 2012 |  |  |  |  |  |  |  |  |  |  | 200,000 |  |  |
Total project estimated to cost |  |  |  |  |  |  |  |  | $ 2,700,000 |  | 2,700,000 |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  | 0 | 300,000 |  |
Fred Hutchinson Cancer Research Center [Member] | License and sponsored research agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones Payments |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |
Description of royalty payment |  |  |  |  |  |  |  | Royalty payments of 2% of net sales will be due to FHCRC. |  |  |  |  |  |
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years ) |  |  |  |  |  |  |  | $ 200,000 |  |  |  |  |  |
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter ) |  |  |  |  |  |  |  | 300,000 |  |  |  |  |  |
Research recorded fees |  |  |  |  |  |  |  |  |  |  | 44,000 | 400,000 |  |
Fred Hutchinson Cancer Research Center [Member] | Maximum [Member] | License and sponsored research agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical trial cost for approval of food and drug administration |  |  |  |  |  |  |  | 23,500,000 |  |  |  |  |  |
Fred Hutchinson Cancer Research Center [Member] | Minimum [Member] | License and sponsored research agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical trial cost for approval of food and drug administration |  |  |  |  |  |  |  | $ 13,200,000 |  |  |  |  |  |
Medpace, Inc. [Member] | CRO Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments and Contingencies (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total project estimated to cost |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,200,000
Research and development costs |  |  |  |  |  |  |  |  |  |  | $ 1,400,000 | $ 1,600,000 |  |

X
- Definition Clinical trial cost for approval of food and drug administration. + References No definition available. + Details
Name: | atnm_ClinicalTrialCostForApprovalForFoodAndDrugAdministration
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | atnm_CommitmentsAndContingenciesTextualAbstract
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of royalty payment to related party. + References No definition available. + Details
Name: | atnm_DescriptionOfRoyaltyPaymentToRelatedParty
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The payment typically represents only a percentage of the full purchase price. A down payment is a type of payment made in cash during the onset of the purchase of an expensive good or service. + References No definition available. + Details
Name: | atnm_DownPayment
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Down payment for project. + References No definition available. + Details
Name: | atnm_DownPaymentForProject
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of total estimated project cost required for down payment. + References No definition available. + Details
Name: | atnm_DownPaymentOfProjectEstimatedCostPercentage
Namespace Prefix: | atnm_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition First commercial sale period. + References No definition available. + Details
Name: | atnm_FirstCommercialSalePeriod
Namespace Prefix: | atnm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fund to related party under agreement after year two. + References No definition available. + Details
Name: | atnm_FundToRelatedPartyUnderAgreementAfterYearTwo
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fund to related party under agreement for first two Year. + References No definition available. + Details
Name: | atnm_FundToRelatedPartyUnderAgreementForFirstTwoYear
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Lease agreements description. + References No definition available. + Details
Name: | atnm_LeaseAgreementsDescription
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Lease term. + References No definition available. + Details
Name: | atnm_LeaseTerm
Namespace Prefix: | atnm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Long term purchase commitment milestones payment. + References No definition available. + Details
Name: | atnm_LongTermPurchaseCommitmentMilestonesPayment
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable institutional fee. + References No definition available. + Details
Name: | atnm_NonRefundableInstitutionalFee
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Project estimated cost. + References No definition available. + Details
Name: | atnm_ProjectEstimatedCost
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty of net sales percentage. + References No definition available. + Details
Name: | atnm_RoyaltyOfNetSalesPercentage
Namespace Prefix: | atnm_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.12) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_Deposits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The current amount of expenditures for a real estate project that has not yet been completed. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.10) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details
Name: | us-gaap_DevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement. + References No definition available. + Details
Name: | us-gaap_PaymentsForLeasingCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3255-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(f)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_ProceedsFromLinesOfCredit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | atnm_AgreementAxis=atnm_ManufacturingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | atnm_AgreementAxis=atnm_CROAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_AbbviewBiotherapeuticsCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | atnm_AgreementAxis=atnm_ProductDevelopmentAndPatentLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=atnm_AfterFirstNetSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=atnm_PhaseFirstClinicalTrialOfLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=atnm_PhaseSecondClinicalTrialOfLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_AbbottBioTherapeuticsCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_OakRidgeNationalLaboratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_IconClinicalResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_FredHutchinsonCancerResearchCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | atnm_AgreementAxis=atnm_LicenseAndSponsoredResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atnm_MedpaceIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |